Avascular Necrosis (Osteonecrosis) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Avascular Necrosis (Osteonecrosis) Market Outlook

Thelansis’s “Avascular Necrosis (Osteonecrosis) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Avascular Necrosis (Osteonecrosis) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Avascular Necrosis (Osteonecrosis) Overview

Avascular necrosis (AVN) of the femoral head is caused by the interruption of blood supply to the bone of the proximal femur. The loss of blood supply can result from both traumatic and non-traumatic causes and leads to cell death (osteonecrosis). Significant necrosis leads to the total collapse of the overlying articular cartilage of the femoral head secondary to the underlying necrotic subchondral bone failure. This occurs before revascularization and regeneration of the necrotic bone can occur due to loss of the underlying structural rigidity of the affected bone as osteoclasts resorb it. The end result of this process is early osteoarthritis (OA) of the hip. The patient will often require a total hip replacement as the osteoarthritis progresses. AVN occurs in 15% to 50% of cases of femoral neck and head fractures and 10% to 25% of hip dislocations. Internal fixation is generally preferred in young patients to save the natural femoral head after a fracture. In contrast, in older patients and elderly patients, primary arthroplasty may be performed to restore mobility.

• Total diagnosed avascular necrosis (AVN) cases range from 25,500 to 31,750 cases yearly in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: